Drug Type Monoclonal antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism Bet v 1 inhibitors(Bet v 1 Protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anaphylaxis | Phase 3 | Canada | 19 Nov 2024 | |
Conjunctivitis | Preclinical | Germany | 14 Jan 2021 | |
Conjunctivitis | Preclinical | United States | 14 Jan 2021 | |
Conjunctivitis | Preclinical | Denmark | 14 Jan 2021 | |
Conjunctivitis | Preclinical | Belgium | 14 Jan 2021 | |
Rhinitis, Allergic, Seasonal | Preclinical | Germany | 14 Jan 2021 | |
Rhinitis, Allergic, Seasonal | Preclinical | Canada | 14 Jan 2021 | |
Rhinitis, Allergic, Seasonal | Preclinical | Belgium | 14 Jan 2021 | |
Rhinitis, Allergic, Seasonal | Preclinical | Denmark | 14 Jan 2021 | |
Rhinitis, Allergic, Seasonal | Preclinical | United States | 14 Jan 2021 |
Phase 3 | 353 | dfjpgbwxqo(hjrcuoiqbi) = okydyqtydc vqmqccjgkj (djtuhfghcy, lgctwkfwxg - oahezqufgx) View more | - | 27 Oct 2022 | |||
Placebo (Placebo Only) | dfjpgbwxqo(hjrcuoiqbi) = poiyeojeqh vqmqccjgkj (djtuhfghcy, ybpifsgmve - emyzkcdyfr) View more |